Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Needs Quantitative Risk/Benefit Analysis To Quell Industry Approval Fears

Executive Summary

Quantitative measures to evaluate drug risks and benefits would provide FDA a stronger defense against critiques of regulatory decisions, several agency observers suggested

You may also be interested in...



PDUFA Pilots: Risk/Benefit Plan Takes Off As “Continuous” Applications Stop

FDA's proposals for renewal of the Prescription Drug User Fee Act will continue the program's function as an incubator of new regulatory approaches by the agency

PDUFA Pilots: Risk/Benefit Plan Takes Off As “Continuous” Applications Stop

FDA's proposals for renewal of the Prescription Drug User Fee Act will continue the program's function as an incubator of new regulatory approaches by the agency

Innovative Drug Development Demands Clearer Regulatory Pathways From FDA

Speeding development of innovative therapies requires FDA to more clearly define regulatory pathways for novel drugs, former Abbott Pharma President & COO Jeffrey Leiden said

Related Content

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel